MX2010001936A - Neuroproteccion utilizando mimeticos de peptido semejantes a nap y semejantes a sal. - Google Patents

Neuroproteccion utilizando mimeticos de peptido semejantes a nap y semejantes a sal.

Info

Publication number
MX2010001936A
MX2010001936A MX2010001936A MX2010001936A MX2010001936A MX 2010001936 A MX2010001936 A MX 2010001936A MX 2010001936 A MX2010001936 A MX 2010001936A MX 2010001936 A MX2010001936 A MX 2010001936A MX 2010001936 A MX2010001936 A MX 2010001936A
Authority
MX
Mexico
Prior art keywords
nap
sal
neuroprotection
peptide mimetics
peptides
Prior art date
Application number
MX2010001936A
Other languages
English (en)
Inventor
Illana Gozes
Alistair Stewart
Maya Maor
Sharon Furman-Assaf
Original Assignee
Univ Ramot
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ramot filed Critical Univ Ramot
Publication of MX2010001936A publication Critical patent/MX2010001936A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención es concerniente con péptidos que imitan los péptido neuroprotectores NAPVISPQ (NAP) y SALLRSIPA (SAL) y su uso en el tratamiento de disfunción neuronal, alteraciones degenerativas, déficit cognoscitivos, alteraciones neuropsiquiatrías y enfermedad autoinrnune.
MX2010001936A 2007-08-24 2008-08-22 Neuroproteccion utilizando mimeticos de peptido semejantes a nap y semejantes a sal. MX2010001936A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95779007P 2007-08-24 2007-08-24
PCT/CA2008/001497 WO2009026687A1 (en) 2007-08-24 2008-08-22 Neuroprotection using nap-like and sal-like peptide mimetics

Publications (1)

Publication Number Publication Date
MX2010001936A true MX2010001936A (es) 2010-08-09

Family

ID=40386607

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010001936A MX2010001936A (es) 2007-08-24 2008-08-22 Neuroproteccion utilizando mimeticos de peptido semejantes a nap y semejantes a sal.

Country Status (12)

Country Link
US (2) US8324166B2 (es)
EP (1) EP2201034A4 (es)
JP (1) JP2010536801A (es)
KR (1) KR20100063719A (es)
CN (1) CN101848934A (es)
AU (1) AU2008291652A1 (es)
BR (1) BRPI0815752A2 (es)
CA (1) CA2695559A1 (es)
MX (1) MX2010001936A (es)
NZ (1) NZ583260A (es)
RU (1) RU2010111114A (es)
WO (1) WO2009026687A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613740B1 (en) * 1997-02-07 2003-09-02 Ramot University Authority For Applied Research And Industrial Development Ltd. Activity dependent neurotrophic factor III (ADNF III)
US7384908B1 (en) * 1999-08-18 2008-06-10 National Institute Of Health Orally active peptides that prevent cell damage and death
WO2003022226A2 (en) * 2001-09-12 2003-03-20 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Neurotrophic components of the adnf i complex
US7960334B2 (en) * 2003-03-12 2011-06-14 Ramot At Tel-Aviv University Ltd. Use of ADNF III polypeptides for treating mental diseases and disorders, including schizophrenia
EP1885389A4 (en) * 2005-03-23 2012-04-04 Univ Ramot USE OF ADNF POLYPEPTIDES FOR THE TREATMENT OF PERIPHERAL NEUROTICITY
US8067369B2 (en) * 2006-02-24 2011-11-29 Ramot At Tel-Aviv University Protection of the retina against laser injury by NAP and related peptides
WO2011021186A1 (en) * 2009-08-17 2011-02-24 Ramot At Tel-Aviv University, Ltd. Nap alpha-aminoisobutyric acid analog with neuroprotective activity
US9518994B2 (en) 2010-01-06 2016-12-13 Ramot At Tel Aviv University Method for diagnosing and monitoring schizophrenia and tauopathies
WO2012015910A2 (en) * 2010-07-28 2012-02-02 Allon Therapeutics Inc. Use of adnf polypeptides for treating neurodegenerative diseases
WO2013171595A1 (en) 2012-05-16 2013-11-21 Ramot At Tel-Aviv University Ltd. Novel compounds and methods for inhibiting cell death
CN105017406B (zh) * 2014-04-21 2020-10-09 上海市第一人民医院 一类新的具有神经保护功能的多肽
WO2017130190A1 (en) * 2016-01-28 2017-08-03 Ramot At Tel-Aviv University Ltd. Novel formulation of neuroprotective peptides
US10100082B2 (en) * 2016-03-07 2018-10-16 Council Of Scientific And Industrial Research Hexapeptide for neuroprotection against a β toxicity

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6174862B1 (en) * 1991-04-22 2001-01-16 Ramot University Authority For Applied Research And Industrial Development, Ltd. Neurotrophic peptides of activity dependent neurotrophic factor
US6613740B1 (en) * 1997-02-07 2003-09-02 Ramot University Authority For Applied Research And Industrial Development Ltd. Activity dependent neurotrophic factor III (ADNF III)
US6933277B2 (en) * 1999-03-12 2005-08-23 The United States Of America As Represented By The Department Of Health And Human Services Prevention of fetal alcohol syndrome and neuronal cell death with ADNF polypeptides
US6649411B2 (en) * 1999-07-30 2003-11-18 The United States Of America As Represented By The Department Of Health And Human Services Methods of inhibiting cancer cells with ADNF III antisense oligonucleotides
ATE266044T1 (de) * 1999-08-18 2004-05-15 Univ Ramot Oral wirksame peptide, die zellschädigung und zelltod verhindern
US7384908B1 (en) * 1999-08-18 2008-06-10 National Institute Of Health Orally active peptides that prevent cell damage and death
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
AUPQ776100A0 (en) * 2000-05-26 2000-06-15 Australian National University, The Synthetic molecules and uses therefor
EP1285000B1 (en) * 2000-05-31 2004-11-24 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Adnf mixtures for enhancing learning and memory
WO2003022226A2 (en) * 2001-09-12 2003-03-20 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Neurotrophic components of the adnf i complex
US7960334B2 (en) * 2003-03-12 2011-06-14 Ramot At Tel-Aviv University Ltd. Use of ADNF III polypeptides for treating mental diseases and disorders, including schizophrenia
EP1885389A4 (en) * 2005-03-23 2012-04-04 Univ Ramot USE OF ADNF POLYPEPTIDES FOR THE TREATMENT OF PERIPHERAL NEUROTICITY
TWI303567B (en) * 2005-12-20 2008-12-01 Ind Tech Res Inst Oligopeptide, derivative thereof, and pharmaceutical composition comprising the same
US8067369B2 (en) * 2006-02-24 2011-11-29 Ramot At Tel-Aviv University Protection of the retina against laser injury by NAP and related peptides

Also Published As

Publication number Publication date
KR20100063719A (ko) 2010-06-11
NZ583260A (en) 2012-07-27
EP2201034A4 (en) 2011-05-18
CA2695559A1 (en) 2009-03-05
US8324166B2 (en) 2012-12-04
AU2008291652A1 (en) 2009-03-05
BRPI0815752A2 (pt) 2015-02-18
JP2010536801A (ja) 2010-12-02
CN101848934A (zh) 2010-09-29
RU2010111114A (ru) 2011-09-27
US20100216723A1 (en) 2010-08-26
WO2009026687A1 (en) 2009-03-05
US20130123186A1 (en) 2013-05-16
EP2201034A1 (en) 2010-06-30

Similar Documents

Publication Publication Date Title
MX2010001936A (es) Neuroproteccion utilizando mimeticos de peptido semejantes a nap y semejantes a sal.
ZA200800464B (en) Peptides for use in the treatment of obesity
PT2069324E (pt) Amino piridina fundida como inibidor da hsp90
LT1854477T (lt) Peptidai, slopinantys plazmos kalikreiną, skirti naudoti oftalmologinių sutrikimų gydymui
WO2009061411A3 (en) Use melanocortins to treat insulin sensitivity
EP2083846A4 (en) FGF N-TERMINAL VARIANTS WITH ENHANCED RECEIVER RECEPTOR AND USES THEREOF
MY181969A (en) Anti-n3pglu amyloid beta peptide antibodies and uses thereof
EP1786515A4 (en) TREATMENT OF THE VEGETABLE NERVOUS SYSTEM
RU2016140850A (ru) Генная терапия нейродегенеративных нарушений
MX2009009261A (es) Anticuerpos anti-ip-10 y metodos para su uso.
WO2006023359A3 (en) Selective vpac2 receptor peptide agonists
ATE389670T1 (de) Selektive peptidische agonisten des vpac2- rezeptors
MX350046B (es) Tratamientos para trastornos gastrointestinales.
NO20082345L (no) Selektive VPAC2 reseptorpeptidagonister
TN2010000214A1 (en) Methods for treating obesity and obesity related diseases and disorders
EP1918297A4 (en) PEPTIDE INDUCING NEURONAL DIFFERENTIATION AND APPLYING THEREOF
CR11692A (es) USO DE VARIANTES DE IGF-I PEGiladas PARA EL TRATAMIENTO DE TRASTORNOS NEUROMUSCULARES
WO2007101146A3 (en) Selective vpac2 receptor peptide agonists
WO2007133828A3 (en) Selective vpac2 receptor peptide agonists
ZA201003037B (en) Use of 3, 11b-cis-dihydrotettabenazine in the treatment of multiple sclerosis and autoimmune myelitis
IL211459A0 (en) Pancreatic polypeptide and variants thereof for use in the treatment of intestinal disorders
SG11201705986QA (en) Antibody molecules and peptide delivery systems for use in alzheimer's disease and related disorders
ATE524487T1 (de) Tau peptidmimetikum zur behandlung von neurodegenerativen erkrankungen
TN2009000135A1 (en) Use of modified cyclosporins
ATE412010T1 (de) Selektive peptidische agonisten des vpac2- rezeptors

Legal Events

Date Code Title Description
FG Grant or registration